BR112023001638A2 - Métodos de tratamento de linfomas mutantes - Google Patents

Métodos de tratamento de linfomas mutantes

Info

Publication number
BR112023001638A2
BR112023001638A2 BR112023001638A BR112023001638A BR112023001638A2 BR 112023001638 A2 BR112023001638 A2 BR 112023001638A2 BR 112023001638 A BR112023001638 A BR 112023001638A BR 112023001638 A BR112023001638 A BR 112023001638A BR 112023001638 A2 BR112023001638 A2 BR 112023001638A2
Authority
BR
Brazil
Prior art keywords
methods
lymphomas
mutant
treatment
degraders
Prior art date
Application number
BR112023001638A
Other languages
English (en)
Inventor
Walker Duncan
Original Assignee
Kymera Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kymera Therapeutics Inc filed Critical Kymera Therapeutics Inc
Publication of BR112023001638A2 publication Critical patent/BR112023001638A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

MÉTODOS DE TRATAMENTO DE LINFOMAS MUTANTES. A presente invenção refere-se a métodos de tratamento de linfomas de células B com mutação em MYD88 usando degradadores de IRAK4.
BR112023001638A 2020-07-30 2021-07-29 Métodos de tratamento de linfomas mutantes BR112023001638A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063058891P 2020-07-30 2020-07-30
US202063109854P 2020-11-04 2020-11-04
US202163202242P 2021-06-02 2021-06-02
PCT/US2021/071048 WO2022027058A1 (en) 2020-07-30 2021-07-29 Methods of treating mutant lymphomas

Publications (1)

Publication Number Publication Date
BR112023001638A2 true BR112023001638A2 (pt) 2023-02-23

Family

ID=80036177

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023001638A BR112023001638A2 (pt) 2020-07-30 2021-07-29 Métodos de tratamento de linfomas mutantes

Country Status (12)

Country Link
US (1) US11857535B2 (pt)
EP (1) EP4188374A1 (pt)
JP (1) JP2023536462A (pt)
KR (1) KR20230044480A (pt)
CN (1) CN116133692A (pt)
AU (1) AU2021316053A1 (pt)
BR (1) BR112023001638A2 (pt)
CA (1) CA3187255A1 (pt)
IL (1) IL300175A (pt)
MX (1) MX2023001217A (pt)
TW (1) TW202220653A (pt)
WO (1) WO2022027058A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024073507A1 (en) 2022-09-28 2024-04-04 Theseus Pharmaceuticals, Inc. Macrocyclic compounds and uses thereof
CN115572768B (zh) * 2022-11-04 2023-12-19 山东第一医科大学附属省立医院(山东省立医院) 一种针对弥漫大b细胞淋巴瘤的预后评估及联合治疗

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4980715B2 (ja) 2003-05-30 2012-07-18 ジェミン エックス ファーマシューティカルズ カナダ インコーポレイテッド がんまたはウイルス疾患を治療するための三環性複素環化合物、組成物および方法
TWI380996B (zh) 2004-09-17 2013-01-01 Hoffmann La Roche 抗ｏｘ４０ｌ抗體
ES2432091T5 (es) 2005-03-25 2022-03-18 Gitr Inc Moléculas de unión GITR y usos de las mismas
PT1888550E (pt) 2005-05-12 2014-09-03 Abbvie Bahamas Ltd Promotores de apoptose
CN104356236B (zh) 2005-07-01 2020-07-03 E.R.施贵宝&圣斯有限责任公司 抗程序性死亡配体1(pd-l1)的人单克隆抗体
US8394794B2 (en) 2007-03-23 2013-03-12 Regents Of The University Of Minnesota Therapeutic compounds
EP1987839A1 (en) 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
ES2591281T3 (es) 2007-07-12 2016-11-25 Gitr, Inc. Terapias de combinación que emplean moléculas de enlazamiento a GITR
EP2044949A1 (en) 2007-10-05 2009-04-08 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
EP2227233B1 (en) 2007-11-30 2013-02-13 Newlink Genetics Ido inhibitors
JP2011518841A (ja) 2008-04-24 2011-06-30 ニューリンク ジェネティクス， インコーポレイテッド Ｉｄｏ阻害剤
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
PE20120341A1 (es) 2008-12-09 2012-04-24 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t
US8921037B2 (en) 2008-12-16 2014-12-30 Bo Han PF4-depleted platelet rich plasma preparations and methods for hard and soft tissue repair
US8709424B2 (en) 2009-09-03 2014-04-29 Merck Sharp & Dohme Corp. Anti-GITR antibodies
WO2011056652A1 (en) 2009-10-28 2011-05-12 Newlink Genetics Imidazole derivatives as ido inhibitors
ES2722300T3 (es) 2009-12-10 2019-08-09 Hoffmann La Roche Anticuerpos que se unen preferentemente al dominio extracelular 4 de CSF1R y su uso
CA2791658C (en) 2010-03-04 2019-10-01 Macrogenics, Inc. Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
RU2617966C2 (ru) 2010-03-05 2017-04-28 Ф.Хоффманн-Ля Рош Аг Антитела против csf-1r человека и их применение
US9169323B2 (en) 2010-03-05 2015-10-27 Hoffmann-La Roche Inc. Antibodies against human CSF-1R
WO2011140249A2 (en) 2010-05-04 2011-11-10 Five Prime Therapeutics, Inc. Antibodies that bind csf1r
SG10201506906VA (en) 2010-09-09 2015-10-29 Pfizer 4-1bb binding molecules
NO2694640T3 (pt) 2011-04-15 2018-03-17
CA2833636A1 (en) 2011-04-20 2012-10-26 Amplimmune, Inc. Antibodies and other molecules that bind b7-h1 and pd-1
LT2785375T (lt) 2011-11-28 2020-11-10 Merck Patent Gmbh Anti-pd-l1 antikūnai ir jų panaudojimas
CN104159921B (zh) 2011-12-15 2018-05-04 霍夫曼-拉罗奇有限公司 针对人csf-1r的抗体及其用途
RU2014136332A (ru) 2012-02-06 2016-03-27 Дженентек, Инк. Композиции и способы применения ингибиторов csf1r
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
RU2670743C9 (ru) 2012-05-11 2018-12-19 Файв Прайм Терапьютикс, Инк. Способы лечения состояний антителами, которые связывают рецептор колониестимулирующего фактора 1 (csf1r)
UY34887A (es) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
RU2718751C2 (ru) 2012-08-31 2020-04-14 Файв Прайм Терапьютикс, Инк. Способы лечения патологических состояний антителами, которые связываются с рецептором колониестимулирующего фактора 1 (csf1r)
EP3710443A1 (en) 2017-11-17 2020-09-23 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 4 polypeptides
US10874743B2 (en) * 2017-12-26 2020-12-29 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
WO2019160915A1 (en) * 2018-02-14 2019-08-22 Dana-Farber Cancer Institute, Inc. Irak degraders and uses thereof
WO2020010227A1 (en) 2018-07-06 2020-01-09 Kymera Therapeutics, Inc. Protein degraders and uses thereof
CN112969696A (zh) 2018-11-02 2021-06-15 达纳-法伯癌症研究公司 乙酰化书写器抑制剂的开发及其用途
BR112021010484A2 (pt) 2018-11-30 2021-08-24 Kymera Therapeutics, Inc. Degradadores de irak e usos dos mesmos
MX2021015995A (es) 2019-06-28 2022-03-11 Kymera Therapeutics Inc Degradadores de cinasas asociadas al receptor de interleucina-1 (irak) y usos de los mismos.
BR112022011651A2 (pt) * 2019-12-17 2022-08-23 Kymera Therapeutics Inc Degradadores de irak e usos dos mesmos

Also Published As

Publication number Publication date
KR20230044480A (ko) 2023-04-04
MX2023001217A (es) 2023-03-03
US11857535B2 (en) 2024-01-02
CN116133692A (zh) 2023-05-16
TW202220653A (zh) 2022-06-01
EP4188374A1 (en) 2023-06-07
CA3187255A1 (en) 2022-02-03
IL300175A (en) 2023-03-01
WO2022027058A1 (en) 2022-02-03
US20220054453A1 (en) 2022-02-24
JP2023536462A (ja) 2023-08-25
AU2021316053A1 (en) 2023-03-02

Similar Documents

Publication Publication Date Title
BR112023001638A2 (pt) Métodos de tratamento de linfomas mutantes
CL2018003213A1 (es) Inhibidores enzimáticos.
ECSP21001499A (es) Anticuerpos dirigidos contra il-11ra
MX2022001607A (es) Composiciones y metodos para tratar la psoriasis y la dermatitis atopica usando prevotella histicola.
CO2017006230A2 (es) Compuestos de n-((het)arilmetil)-heteroaril-carboxamidas como inhibidores de calicreína plasmática
MX2020001757A (es) Compuestos, sales de los mismos y metodos para el tratamiento de enfermedades.
CO2020010552A2 (es) Compuestos
AU2019428645B2 (en) Adjustably tensioned roller massage system
MX2017014797A (es) Metodos y kits para tratar la depresion.
BR112017021312A2 (pt) tratamento de câncer de pulmão com inibidores de glutaminase
AU2019243283C1 (en) Methods of treating ulcerative colitis
EA201890968A1 (ru) Комбинированная терапия для лечения злокачественных новообразований
MA47408B1 (fr) Traitement du cancer
CY1125071T1 (el) Θεραπεια του συνδρομου ευθραυστου χ με κανναβιδιολη
BR112021020409A2 (pt) Terapia de combinação com anticorpo anti-bcma e inibidor de gama-secretase
MX2021016049A (es) Metodos de uso de inhibidores de rad51 para el tratamiento de cancer de pancreas.
MA46459B1 (fr) Méthode de traitement de lésions rénales aiguës
ZA202006612B (en) Antibacterial compounds
ATE484623T1 (de) Behandlung von textilien mit silikonpolyetheramidblockcopolymeren
BR112022001054A2 (pt) Inibidores enzimáticos
BR112022021562A2 (pt) Partículas interferentes terapêuticas para o coronavírus
MX2019004804A (es) Tratamiento para el prurigo nodula.
BR112022000936A2 (pt) Inibidores de enzimas
PH12019550183A1 (en) Treatment of infant colic
ZA202103975B (en) Methods of treating disease with magl inhibitors